Drugs / Transdermal estrogen
Transdermal estrogen
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06271551 | Mar 2024 → Dec 2028 expected | prostate cancer | Central Finland Hospital District | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Transdermal estrogen | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06271551 ↗ |
| Known as | EstroGel | “ESTRACISE participants allocated to the transdermal estradiol arm will use transdermal estradiol gel (E2) as a dose of 750 ug (EstroGel 0.6 mg/ml) in addition to androgen...” NCT06271551 ↗ |
| Known as | oestradiol | “To report the protocol of a study evaluating the efficacy of transdermal oestradiol (E2) gel in reducing the adverse effects of androgen deprivation therapy (ADT), specifically...” PMID 38587276 ↗ Apr 2024 |